Drug Interaction Report

Mepenzolate and Buprenorphine: Interaction Details

AI-assisted, pharmacist-reviewed · AI content regenerated Jul 11, 2026 · Source data updated Jul 2, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature

Buprenorphine

Belbuca Brixadi Buprenex BuTrans Simbadol Sublocade Zorbium
+

Mepenzolate

No brand names on record
Dr. Brian Staiger, PharmD, BCPS
Medically reviewed by
Updated Jul 2, 2026
LinkedIn
Interaction severity
Major
Potentially serious — often needs a change or close monitoring.
How we grade severity & evidence

Severity levels

  • Contraindicated: These should generally not be used together.
  • Major: Potentially serious — often needs a change or close monitoring.
  • Moderate: Can be significant — usually manageable with monitoring.
  • Minor: Usually limited clinical impact.

Evidence grades

  • Established: Well documented — supported by controlled studies or strong clinical data.
  • Probable: Good supporting evidence, though not definitively proven.
  • Suspected: Some evidence suggests this interaction, but it is not well established.
  • Possible: Limited or conflicting evidence; the interaction may occur.
  • Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.

Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.

Of 12 documented Mepenzolate interactions, 11 are rated major — including this one.
Worried about symptoms right now? Contact your pharmacist or prescriber, or call Poison Control at 1-800-222-1222 (US). Call 911 for an emergency.
At a glance + Theoretical Effects may be stronger
The Bottom Line
Taking buprenorphine with mepenzolate can add up to cause severe constipation, urinary retention, or rarely a stalled bowel; watch for these symptoms and tell your care team, but keep taking both as prescribed.

You've been prescribed buprenorphine (an opioid pain or addiction medicine) along with mepenzolate (a medicine that calms stomach and gut spasms). Both of these can slow down how your bowels move. When taken together, that slowing can add up.

The main worry is severe constipation or trouble emptying your bladder. In rare cases, the gut can slow so much that it nearly stops, which doctors call a paralytic ileus. Please know this concern is based on how the drugs work in theory, not on lots of real-world cases. Watch for a swollen or painful belly, no bowel movements, or trouble urinating, and tell your care team. They can manage this well by keeping an eye on you.

Effect: Additive reduction in GI motility with combined buprenorphine (opioid) and mepenzolate (antimuscarinic/anticholinergic), increasing risk of severe constipation, urinary retention, and potentially paralytic ileus.

Mechanism: Pharmacodynamic additive effect. Opioids reduce gut motility via mu-receptor activation; anticholinergics further impair smooth muscle motility and bladder emptying. Neither drug is a prodrug; direction is additive PD, not PK.

Evidence: Theoretical. Onset: unspecified. Severity: major.

Management:

  • Monitor for reduced gastric motility, abdominal distension, and urinary retention.
  • Consider bowel regimen; individualize therapy.
  • Reassess if obstructive symptoms emerge.
Onset
unspecified
Evidence
theoretical
Severity
Major

What happens

An increased risk of paralytic ileus

Interaction Deep Dive

When buprenorphine is given together with an anticholinergic agent, the combination may lead to urinary retention or to severe constipation that progresses to paralytic ileus. In patients receiving buprenorphine alongside anticholinergic drugs, watch for indications of urinary retention or diminished gastric motility1.

Why it happens (mechanism)

Additive effects on gastric motility

How to manage this interaction

Keep taking both medicines exactly as prescribed unless your care team tells you otherwise. This is a manageable combination when watched appropriately.

  • Watch for warning signs: no bowel movements, a hard or swollen belly, belly pain, nausea/vomiting, or difficulty urinating.
  • Support your gut: ask your pharmacist whether a stool softener or laxative and good fluid intake would help, since constipation is the main concern.
  • Report promptly: contact your pharmacist or prescriber if bowel or bladder symptoms appear.

Your care team may monitor you more closely and adjust and individualize your treatment as needed.

Management is individual — confirm any change with your pharmacist or prescriber.

Common questions

Can I take Mepenzolate and Buprenorphine together?

Taking buprenorphine with mepenzolate can add up to cause severe constipation, urinary retention, or rarely a stalled bowel; watch for these symptoms and tell your care team, but keep taking both as prescribed. Always confirm with your pharmacist or prescriber before making any change.

How serious is the Mepenzolate and Buprenorphine interaction?

It is rated major. Potentially serious — often needs a change or close monitoring.

How quickly could this interaction happen?

The documented onset is "unspecified". The timing of this interaction is not well characterized.

How is the Mepenzolate and Buprenorphine interaction managed?

Keep taking both medicines exactly as prescribed unless your care team tells you otherwise. This is a manageable combination when watched appropriately. Watch for warning signs: no bowel movements, a hard or swollen belly, belly pain, nausea/vomiting, or difficulty urinating. Support your gut: ask your pharmacist whether a stool softener or laxative and good fluid intake would help, since constipa… Management is individual — always follow your own care team's guidance.

How strong is the evidence for this interaction?

The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.

Questions for your pharmacist

  • Does my dose of Mepenzolate or Buprenorphine need adjusting while I take them together?
  • What symptoms should prompt me to call you or my prescriber right away?
  • Does the timing of my doses matter for this combination?
  • Is there a safer alternative to one of these medications for me?

References (1)

  1. Product Information: BRIXADI(TM) subcutaneous extended-release injection, buprenorphine subcutaneous extended-release injection. Braeburn Inc (per FDA), Plymouth Meeting, PA, 2023. DailyMed
Was this write-up helpful?
Beyond drug–drug

These medications also interact with supplements

Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:

major · moderate · minor — check everything you take with our drug–supplement interaction checker.

Check another combination

Our instant two-drug interaction checker is almost here.

Coming soon

The instant two-drug checker is on its way.

In the meantime, browse the directory below to look up any drug and see its documented interactions.

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist
This information is for education, not a substitute for professional medical advice. Do not start, stop, or change any medication without talking to your pharmacist or prescriber.